Nurix CLO granted options and 42,875 RSUs

Q: What equity awards did Nurix (NRIX) grant to its Chief Legal Officer?

Nurix granted Chief Legal Officer Christine Ring an option to buy 93,750 shares of common stock at $16.45 per share and 42,875 RSUs. These awards are part of her equity-based compensation and vest over multiple years.

Q: How do the new stock options for Nurix (NRIX) Chief Legal Officer vest?

The 93,750-share stock option vests in 1/36 monthly installments starting March 10, 2026. It becomes fully vested by February 9, 2029, provided Christine Ring continues to provide services to Nurix on each vesting date.

Q: What is the vesting schedule for the Nurix (NRIX) RSUs granted to the Chief Legal Officer?

The 42,875 RSUs vest in 1/12 quarterly installments over three years, with the first vesting date on July 30, 2026. After each vesting date, one share of common stock is delivered for each vested RSU, subject to continued service.

Q: What does each restricted stock unit (RSU) granted by Nurix (NRIX) represent?

Each RSU represents a contingent right to receive one share of Nurix common stock. RSUs do not have an exercise price and either vest or are canceled before vesting, depending on continued service and plan conditions.

Q: Do the Nurix (NRIX) RSUs granted to the Chief Legal Officer have an expiration date?

The RSUs do not have a traditional expiration date. They either vest according to the schedule or are canceled before the vesting date, as described in the award terms and subject to continued service requirements.

Q: What is the exercise price and expiration date of the Nurix (NRIX) stock option grant?

The employee stock option has an exercise price of $16.45 per share and an expiration date of February 9, 2036. The option becomes exercisable gradually as monthly vesting occurs over the three-year vesting period.

Nurix Therapeutics Chief Legal Officer receives new equity awards.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Nurix Therapeutics Chief Legal Officer receives new equity awards. On February 10, 2026, Christine Ring was granted an employee stock option for 93,750 shares of common stock at an exercise price of $16.45 per share and 42,875 restricted stock units.

The stock option vests in equal monthly installments over 36 months beginning March 10, 2026, and is fully vested by February 9, 2029, contingent on continued service. The RSUs vest in 12 quarterly installments over three years starting July 30, 2026, with one share of common stock delivered for each vested unit.

Insider Trade Summary

Grant/Award: 136,625 shares

Grant/Award 2 txns

Insider Ring Christine

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	93,750	$0.00	$0.00
Grant/Award	Restricted Stock Units	42,875	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 93,750 contracts (Direct); Restricted Stock Units — 42,875 contracts (Direct)

Footnotes (4)

F1. The stock option vests as to 1/36 of the total shares monthly beginning March 10, 2026, until the option is fully vested on February 9, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F3. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
F4. RSUs do not expire; they either vest or are canceled prior to the vest date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Nurix (NRIX) grant to its Chief Legal Officer?

Nurix granted Chief Legal Officer Christine Ring an option to buy 93,750 shares of common stock at $16.45 per share and 42,875 RSUs. These awards are part of her equity-based compensation and vest over multiple years.

How do the new stock options for Nurix (NRIX) Chief Legal Officer vest?

The 93,750-share stock option vests in 1/36 monthly installments starting March 10, 2026. It becomes fully vested by February 9, 2029, provided Christine Ring continues to provide services to Nurix on each vesting date.

What is the vesting schedule for the Nurix (NRIX) RSUs granted to the Chief Legal Officer?

The 42,875 RSUs vest in 1/12 quarterly installments over three years, with the first vesting date on July 30, 2026. After each vesting date, one share of common stock is delivered for each vested RSU, subject to continued service.

What does each restricted stock unit (RSU) granted by Nurix (NRIX) represent?

Each RSU represents a contingent right to receive one share of Nurix common stock. RSUs do not have an exercise price and either vest or are canceled before vesting, depending on continued service and plan conditions.

Do the Nurix (NRIX) RSUs granted to the Chief Legal Officer have an expiration date?

The RSUs do not have a traditional expiration date. They either vest according to the schedule or are canceled before the vesting date, as described in the award terms and subject to continued service requirements.

What is the exercise price and expiration date of the Nurix (NRIX) stock option grant?

The employee stock option has an exercise price of $16.45 per share and an expiration date of February 9, 2036. The option becomes exercisable gradually as monthly vesting occurs over the three-year vesting period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/10/2026 - 05:55 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ring Christine

(Last)

(First)

(Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE

94005

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$16.45	02/10/2026		A		93,750		⁽¹⁾	02/09/2036	Common Stock	93,750	$0	93,750	D
Restricted Stock Units	$0⁽²⁾	02/10/2026		A		42,875		⁽³⁾	⁽⁴⁾	Common Stock	42,875	$0	42,875	D

Explanation of Responses:

1. The stock option vests as to 1/36 of the total shares monthly beginning March 10, 2026, until the option is fully vested on February 9, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

3. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

4. RSUs do not expire; they either vest or are canceled prior to the vest date.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR